Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

iwNHL 2015 | Duvelisib, dual inhibitor of PI3K delta and PI3K gamma, for indolent non-Hodgkin lymphoma

Ian Flinn • 3 Oct 2015
iwNHL 2015
Non-Hodgkin Lymphoma Brentuximab vedotin Duvelisib Rituximab

At the International Workshop on Non-Hodgkin Lymphoma (iwNHL) 2015 meeting, Ian Flinn, MD, of Tennessee Oncology, Nashville, TN, discusses the clinical development of duvelisib, a dual inhibitor of phosphoinositide 3-kinase (PI3K) delta and PI3K gamma, for the treatment of patients with indolent non-Hodgkin lymphoma (iNHL). Duvelisib has demonstrated promising clinical activity in patients with relapsed/refractory iNHL and ongoing clinical trials are investigating duvelisib alone and in combination for this disease.

More from Ian Flinn

SGN35-027: Brentuximab vedotin with nivolumab, doxorubicin, and dacarbazine in HL
2:18
SGN35-027: Brentuximab vedotin with nivolumab, doxorubicin, and dacarbazine in HL
Ian Flinn • 9 Dec 2021
Unanswered questions in frontline CLL treatment
0:57
Unanswered questions in frontline CLL treatment
Ian Flinn • 9 Dec 2021
Umbralisib and ublituximab in patients with CLL and comorbidities
1:55
Umbralisib and ublituximab in patients with CLL and comorbidities
Ian Flinn • 9 Dec 2021
Debulking strategies in CLL before venetoclax therapy
2:48
Debulking strategies in CLL before venetoclax therapy
Ian Flinn • 9 Dec 2021

Related Videos

Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
2:30
Exploring CAR-T and bispecifics in CLL: novel approaches beyond BTK and BCL2 inhibitors
Alexey Danilov • 16 Oct 2026
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
2:39
Genomic and immune signatures of ibrutinib response & resistance in Waldenström's macroglobulinemia
Tina Bagratuni • 23 Sep 2026
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
2:13
Unresolved questions in T-cell lymphoma: individualized therapy and access to new technologies
Mary Jo Lechowicz • 11 Sep 2026
Key advances in FL management expected to change practice over the next five years
1:26
Key advances in FL management expected to change practice over the next five years
Kim Linton • 11 Sep 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals